Abstract: BACKGROUND In patients with cardiogenic shock, data on the comparative safety and efficacy of drug-eluting stents (DESs) vs. bare metal stents (BMSs) are lacking. We sought to assess the performance of DESs compared with BMSs among patients with cardiogenic shock undergoing percutaneous coronary intervention (PCI). METHODS Out of 236 patients with acute coronary syndromes complicated by cardiogenic shock, 203 were included in the final analysis. The primary endpoint included death, and the secondary endpoint of major adverse cardiac and cerebrovascular events (MACCEs) included the composite of death, myocardial infarction, any repeat revascularization and stroke. Patients were followed for a minimum of 30 days and up to 4 years. As stent assignment was not random, we performed a propensity score analysis to minimize potential bias. RESULTS Among patients treated with DESs, there was a lower risk of the primary and secondary endpoints compared with BMSs at 30 days (29 vs. 56%, P < 0.001; 34 vs. 58%, P = 0.001, respectively) and during long-term follow-up [hazard ratio 0.43, 95% confidence interval (CI) 0.29-0.65, P < 0.001; hazard ratio 0.49, 95% CI 0.34-0.71, P < 0.001, respectively]. After propensity score adjustment, all-cause mortality was reduced among patients treated with DESs compared with BMSs both at 30 days [adjusted odds ratio (OR) 0.26, 95% CI 0.11-0.62; P = 0.002] and during long-term follow-up (adjusted hazard ratio 0.40, 95% CI 0.22-0.72; P = 0.002). The rate of MACCE was lower among patients treated with DESs compared with those treated with BMSs at 30 days (adjusted OR 0.42, 95% CI 0.19-0.95; P = 0.036). The difference in MACCEs between devices approached significance during long-term follow-up (adjusted hazard ratio 0.60, 95% CI 0.34-1.01; P = 0.052). CONCLUSION DESs appear to be associated with improved clinical outcomes, including a reduction in all-cause mortality compared with BMSs among patients undergoing PCI for cardiogenic shock, possibly because of a pacification of the infarct-related artery by anti-inflammatory drug. The results of this observational study require confirmation in an appropriately powered randomized trial. 
Background In patients with cardiogenic shock, data on the comparative safety and efficacy of drug-eluting stents (DESs) vs. bare metal stents (BMSs) are lacking. We sought to assess the performance of DESs compared with BMSs among patients with cardiogenic shock undergoing percutaneous coronary intervention (PCI).
Methods Out of 236 patients with acute coronary syndromes complicated by cardiogenic shock, 203 were included in the final analysis. The primary endpoint included death, and the secondary endpoint of major adverse cardiac and cerebrovascular events (MACCEs) included the composite of death, myocardial infarction, any repeat revascularization and stroke. Patients were followed for a minimum of 30 days and up to 4 years. As stent assignment was not random, we performed a propensity score analysis to minimize potential bias.
Results Among patients treated with DESs, there was a lower risk of the primary and secondary endpoints compared with BMSs at 30 days (29 vs. 56%, P < 0.001; 34 vs. 58%, P U 0.001, respectively) and during long-term follow-up [hazard ratio 0.43, 95% confidence interval (CI) 0.29-0.65, P < 0.001; hazard ratio 0.49, 95% CI 0.34-0.71, P < 0.001, respectively]. After propensity score adjustment, all-cause mortality was reduced among patients treated with DESs compared with BMSs both at 30 days [adjusted odds ratio (OR) 0.26, 95% CI 0.11-0.62; P U 0.002] and during long-term follow-up (adjusted hazard ratio 0.40, 95%
CI 0.22-0.72; P U 0.002). The rate of MACCE was lower among patients treated with DESs compared with those treated with BMSs at 30 days (adjusted OR 0.42, 95% CI 0.19-0.95; P U 0.036). The difference in MACCEs between devices approached significance during long-term followup (adjusted hazard ratio 0.60, 95% CI 0.34-1.01; P U 0.052).
Conclusion DESs appear to be associated with improved clinical outcomes, including a reduction in all-cause mortality compared with BMSs among patients undergoing PCI for cardiogenic shock, possibly because of a pacification of the infarct-related artery by anti-inflammatory drug. The results of this observational study require confirmation in an appropriately powered randomized trial.
Introduction
Cardiogenic shock is a life-threatening complication of acute coronary syndromes (ACSs) occurring in approximately 5-10% of patients. 1, 2 Indeed, cardiogenic shock is associated with a high mortality ranging between 30 and 80%. [3] [4] [5] This poor prognosis is determined in part by the amount of myocardium at risk, the timeliness of revascularization, the use of assist devices (mechanical support), adjunctive medical therapy and the patients' age. 1, 6 Recently, it has been suggested that the type of stent used in primary percutaneous coronary interventions (pPCIs) might impact on outcomes of patients with ACS. Indeed, drug-eluting stents (DESs) reduce neointimal hyperplasia when compared with bare metal stents (BMSs); however, data on the safety and performance of DESs in ACS are limited. 7, 8 The Harmonizing Outcomes With Revascularization And Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial suggested that paclitaxel-eluting stents may be used in patients with STsegment elevation myocardial infarction (STEMI) for improving the outcomes. 7 However, in line with previous smaller randomized clinical trials, the mortality was similar in both BMS and paclitaxel-eluting stent groups. 7 We recently showed in the randomized biolimus-eluting stents were superior in terms of major adverse cardiac and cardiovascular events (MACCEs) in patients with ACS compared to BMS. 9 A limitation of both the HORIZONS-AMI trial and the COMFORTA-BLE AMI trial, however, was the very small number of patients with cardiogenic shock. 7, 9 Therefore, all-comers studies on patients with AMI would be required for determining the true effects of DES implantation compared with BMS on clinical outcomes in high-risk patients. To address the limitations of previously published data, we aimed to compare DES with BMS in patients with cardiogenic shock using a propensity score analysis to adjust for imbalances in baseline characteristics.
Methods

Patient population
Consecutive patients referred for PCI between 1 June 2007 and 1 July 2012 to the University Heart Centre, Department of Cardiology of the University Hospital of Zurich, with the diagnosis of ACS, were included in the Zurich ACS-Registry, of whom 236 were complicated by cardiogenic shock. All patients with cardiogenic shock on admission were considered for enrollment, if at least one DES or BMS had been implanted. Patients were excluded from the present study, if early surgical revascularization or PCI without stent implantation was performed (Fig. 1) . Patients who received both DES and BMS were also excluded from the final analysis. All patients included in the final analysis (n ¼ 203) were linked to the long-term follow-up. Due to the retrospective nature of this study, the need for informed consent was waived by the institutional review board (local ethics committee, University Hospital Zurich, Switzerland).
Definitions
The diagnosis of STEMI was based on a new ST-segment elevation of at least 1 mm in two or more contiguous leads or if a new left bundle branch block (LBBB) was identified accompanied with elevated cardiac serum troponin T level above the threshold for myocardial necrosis. Non-ST-segment elevation myocardial infarction (NSTEMI) was defined as the elevation of biomarkers of myocardial necrosis (e.g., troponin) without ST-segment elevation in ECG in the setting of angina. Cardiogenic shock was defined as persistent SBP less than 90 mmHg not responsive to fluid supplementation or the need for vasopressor agents with evidence of pulmonary edema and systemic signs of hypoperfusion. 2 Cardiogenic shock was also considered when preserved SBP was more than 100 mmHg achieved by means of vasopressors or intra-aortic balloon pump (IABP) support. 2 Full revascularization was defined as the complete reperfusion of all ischemic myocardial territories. Areas of old infarction with no viable myocardium was not reperfused during the acute course of ACS.
Procedures
Coronary angiography through the femoral access was performed on an Allura 9 (Philips Healthcare, The Leiden, Netherlands) and an Allura XPER FD10/10 (Philips Medical) catheterization equipment in the Andreas Gruentzig Catheterization Laboratories of the University Hospital of Zurich, Switzerland, following a protocol, which consisted of a biplane angiography of the left coronary artery with two radiation exposures in four orientations and of the right coronary artery with two exposures in two orientations. Additional views were performed at the operator's discretion, if necessary. Copyright © Italian Federation of Cardiology. Unauthorized reproduction of this article is prohibited. SYNTAX score analysis SYNTAX score assessment was performed by a cardiologist blinded to the clinical outcomes of the patients using a scoring system for all significant lesions (!50%) in the vessels 1.5 mm or greater in diameter by applying a dedicated SYNTAX score algorithm. SYNTAX score was calculated using angiography just after the first dilatation of the culprit vessel to include all significant lesions. However, if the culprit vessel was occluded before PCI, the lesion was scored as an acute occlusion with the duration of less than 3 months.
Study endpoints
The primary endpoint of the present study was all-cause mortality, and the secondary endpoint MACCE was the composite of death, myocardial infarction (MI), any repeat revascularization and stroke at 30 days and up to 4 years. We also evaluated the rate of ischemia-driven target lesion revascularization (TLR) and definite stent thrombosis as defined by the ARC criteria. TLR was defined as repeat intervention to treat a luminal diameter stenosis of at least 50% in the stent or within the 5-mm borders proximal or distal to the stent and after the event of angina. Postdischarge observation was obtained as part of our hospital quality assurance using a standardized clinical questionnaire.
Statistical analysis
For statistical analysis, IBM SPSS Statistics 20 (IBM Corp, Armonk, New York, USA) was used. Continuous data were expressed as mean values (AEstandard deviation) or median with interquartile range and compared using an independent samples t-test or the Mann-Whitney U-test.
Categorical data were reported as proportions and evaluated by the Pearson's x 2 or the Fisher's exact test, where appropriate. Overall death and MACCEs were analyzed using the Kaplan-Meier time-to-event curves and were compared between DES and BMS using the log-rank test. All tests were two-sided and a P < 0.05 was considered as statistically significant.
As an early benefit of DES would be unlikely, we performed a sensitivity analysis for assessing differences between the two stent groups in all-cause mortality and MACCE 2 days after stent placement.
Furthermore, to limit the observational character of the study, we also performed a propensity score analysis. For the computation of the propensity score, the following variables were included into a nonparsimonious logistic regression with DES as dependent variable: age, sex, STEMI on admission, hypertension, diabetes, smoking, hypercholesterolemia, family history, obesity, known stroke, known MI, known coronary artery disease, heart rate, SBP, DBP, left ventricular ejection fraction, out-ofhospital resuscitation, type of cardiac arrest, use of vasopressors, use of IABP, intubation, one-time urgent full revascularization, Global Registry of Acute Coronary Events (GRACE) score risk, use of glycoprotein IIb/IIIa antagonist and use of thrombectomy; angiographic analysis: SYNTAX score, culprit lesion and its segment, TIMI grade flow before PCI, presence of chronic total occlusion and stent length; laboratory values on admission: creatinine, glomerular filtration rate, myoglobin, creatine kinase, creatine kinase-muscle brain type fraction, N-terminal brain-type natriuretic peptide, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, hemoglobin and red blood cells, white blood cells (WBCs); drug administration before presentation: aspirin, clopidogrel, prasugrel, statin, b-blocker, angiotensin-converting enzyme inhibitors, diuretics, sartans, calcium channel blockers and vitamin K antagonists.
Variables with a skewed distribution were logarithmically transformed before analysis. Missing values were replaced by multiple regression imputation for the respective analysis. The model was well calibrated (the HosmerLemeshow test x 2 8.3, 8 df, P ¼ 0.40) and highly discriminating (c-value 0.91). The validity of logistic regression was assessed using the Hosmer-Lemeshow test and proportional hazard in Cox regression was estimated visually. Finally, logistic regressions for 30-day event rates of death and MACCE, and Cox regressions for long-term death and MACCE, respectively, as dependent variables, and DES and the propensity score, divided in quintiles, as independent variables were performed.
Results
Baseline characteristics
Out of 236 patients, 203 patients with cardiogenic shock were included into the final analysis. Of those, 157 patients (77%) were admitted with the primary diagnosis of STEMI and 46 patients (23%) with NSTEMI. The mean age of the total study population was 63.9 AE 11.6 years, and 79% (n ¼ 160) were men. DESs were implanted in 58% (n ¼ 117) and BMSs in 42% (n ¼ 86) of all patients. Of the patients treated with DESs, 50% (n ¼ 59) received everolimus-eluting stents, 31% (n ¼ 36) received zotarolimus-eluting stents and 19% (n ¼ 22) received other DESs (biolimus-eluting, paclitaxel-eluting, sirolimus-eluting or tacrolimus-eluting stents). The risk profiles of the two groups of patients treated with DES or BMS implantation were similar (Tables 1 and 2 ). The mean number of risk factors was 2.2 AE 1.4 and most patients were classified as high risk by GRACE risk score with a mean value for in-hospital death of 266 AE 30.7 (range 164-338) and the composite of death and MI of 4 Journal of Cardiovascular Medicine 2014, Vol 00 No 00 Glycoprotein IIb/IIIa therapy was administered in 33% of patients (n ¼ 67), whereas thrombectomy was performed in 44% (n ¼ 90) of patients. None of the patients underwent fibrinolysis before presentation. Full revascularization was documented in 78% (n ¼ 158) of patients with a mean stent use of 1.9 AE 1.1 per patient (Table 2 ). There were no complications related to the passage or deployment of the balloon or stent. In one patient, no reflow phenomenon was observed after BMS implantation.
Clinical outcomes
The overall mortality rate at 30 days was 40% (n ¼ 82). In the unadjusted analysis, the primary endpoint of all-cause mortality was significantly lower among patients treated with DESs compared with BMSs at 30 days (29 vs. 56%, P < 0.001) (Fig. 2a) . Similar findings were obtained DES vs. BMS in cardiogenic shock Jaguszewski et al. 5 A 30-day (a) and long-term mortality (b) for patients with drug-eluting stents (DESs) and bare metal stents (BMSs), unadjusted analysis.
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during long-term follow-up [hazard ratio 0.43, 95% confidence interval (CI) 0.29-0.65, P < 0.001) (Fig. 2b ).
Patients treated with DESs showed a better outcome than those receiving BMSs for all-cause mortality, especially at 30 days after the index event. MACCE rate was also lower in patients receiving a DES compared with those receiving a BMS, both at 30 days (34 vs. 58%, P ¼ 0.001) and during long-term follow-up (hazard ratio 0.49, 95% CI 0.34-0.71, P < 0.001) ( Table 3 , Fig. 3a and b) .
The rate of 30-day definite stent thrombosis was similar in both study populations (P ¼ 0.14). Only one case of late stent thrombosis was observed in the DES group. However, the difference in ischemia-driven TLR for DES vs. BMS approached significance at the long-term follow-up (0.8 vs. 6%, respectively; P ¼ 0.066) in this setting.
Propensity score analysis ascertainment
After propensity score adjustment, we noticed a significant reduction in all-cause mortality in patients receiving DESs compared with those receiving BMSs both at 30 days [adjusted odds ratio (OR) 0.26, 95% CI 0.11-0.62; P ¼ 0.002] and during long-term follow-up [adjusted hazard ratio (AHR) 0.40, 95% CI 0.22-0.72; P ¼ 0.002] (Fig. 4a and b) . Similarly, there was a significant difference in the rates of MACCE among patients receiving DESs as compared with BMSs in the propensity score adjustment analysis at 30 days (adjusted OR 0.42, 95% CI 0.19-0.95; P ¼ 0.036) (Fig. 5a ). During long-term followup, the difference between DES and BMS groups approached significance with respect to overall MACCE rate (AHR 0.60, 95% CI 0.34-1.01; P ¼ 0.052) ( Table 3 , Fig. 5b) .
A sensitivity analysis
The significantly lower event rate for long-term death and MACCE among patients treated with DESs as compared with BMSs remained unchanged after exclusion of all events occurring within the first 2 days after admission (hazard ratio 0.44, 95% CI 0.27-0.69, P < 0.001; hazard ratio 0.50, 95% CI 0.33-0.76, P ¼ 0.001, respectively). Likewise, after propensity score adjustment, the long-term rates of death and MACCE in the DES group remained lower compared with the BMS group (AHR 0.34, 95% CI 0.18-0.67, P ¼ 0.002; AHR 0.58, 95% CI 0.33-1.02, P ¼ 0.058, respectively) ( Table 3) .
Discussion
This study for the first time suggests that in patients presenting with an ACS and cardiogenic shock, the implantation of DES is associated both with a lower mortality and a lower risk of MACCE as compared with BMS.
In spite of all the progress made in the management of patients with ACS in the last decades, cardiogenic shock remains a severe complication associated with a markedly increased mortality and MACCE rate compared with hemodynamically stable patients. 2 In the present study, the overall 30-day mortality rate was 40%, which is comparable with those in other shock trials. 10, 11 In the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock trial and in registry data, mortality varied from 22 up to 88% depending on the presence or absence of clinical predictors, including previous MI and the treatment strategies. 10, 11 As expected, early revascularization improved survival rate Copyright © Italian Federation of Cardiology. Unauthorized reproduction of this article is prohibited.
across a broad range of risk strata. 10, 11 In the GRACE registry, fatality rates for cardiogenic shock ranged between 35% for patients receiving revascularization and up to 74% in those not undergoing a pPCI procedure. 4 Indeed, pPCI and coronary stenting are important predictors of in-hospital mortality. 4 Thus, further research is a particular clinical need in this patient population.
So far, it remained unclear whether DES implantation during primary PCI would have a substantial impact on outcomes in patients with cardiogenic shock. Indeed, Champion et al. 12 even reported a trend toward a higher mortality after DES implantation. Therefore, they strongly suggested that DES should not be the treatment of choice in this patient population. 12 These findings were surprising, as a substantial reduction in restenosis rate and revascularization has been documented using DES in many trials enrolling patients with stable CAD 13 and in two trials in patients with ACS. 7, 9 However, so far, randomized trials in patients with ACS (i.e. HORIZONS-AMI, clinical Evaluation of the Xience-V Stent in Acute Myocardial INfArcTION and COMFORTABLE) enrolled only a low proportion of patients with cardiogenic shock and, thus, they did not address the question, whether DESs indeed are advantageous in ACS patients with hemodynamic compromise or high-risk coronary DES vs. BMS in cardiogenic shock Jaguszewski et al. 7 A 30-day (a) and long-term major adverse cardiac and cerebrovascular events (MACCEs) (b) for patients with drug-eluting stents (DESs) and bare metal stents (BMSs), unadjusted analysis. anatomy. 7, 9 Indeed, ACS studies enrolling all-comers documented a markedly higher event rate compared with these randomized trials. 14 In contrast to previous reports, 15, 16 our results based on a markedly larger study population strongly suggest that the use of DESs in patients with cardiogenic shock does indeed provide a substantial survival benefit and a marked reduction in MACCE as compared with BMSs both at 30 days and at long-term follow-up. The majority of patients of this registry would not have been eligible for randomized clinical trials because of their hemodynamic instability, lesion complexity or because of the fact that they had been intubated and/or resuscitated. The clinical and anatomical complexity of the patients is further reflected by their high SYNTAX and GRACE score. [17] [18] [19] As an early benefit of DES implantation appeared unlikely and baseline risk factors could affect the risk of death, we performed a sensitivity analysis, whereby mortality rates were examined 2 days after stent implantation. Importantly, the reduction in long-term MACCE and all-cause mortality with DESs remained significant, indicating the potential for a true benefit of DES in cardiogenic shock. As an operator bias in the selection of BMS in patients with cardiogenic shock and a perceived poor prognosis may have influenced the results, we performed a propensity score analysis to adjust for imbalances. After adjusting for measured confounders, we confirmed a significantly lower rate of 30-day and long-term all-cause mortality and a trend toward a lower rate of MACCE.
The better outcome after DES implantation as compared with BMS in cardiogenic shock at 30 days and during long-term follow-up may be related to the local release of antiproliferative as well as anti-inflammatory agents such as paclitaxel, sirolimus, everolimus, biolimus or zotarolimus, which are known to inhibit inflammation and neointimal proliferation. Indeed, potentially, such anti-inflammatory and immunomodulatory compounds released from DESs may even reduce the production of cytokines such as interleukin-6 and serum amyloid A found at the site of coronary occlusion and in turn affect outcome in these high-risk patients. However, WBC count and hsCRP did not differ in patients receiving a DES or a BMS. Thus, a systemic anti-inflammatory effect of DES is unlikely. However, a local inhibition of the marked inflammatory response at the site of coronary occlusion 20, 21 may still be involved, especially early after DES placement when up to 80% of the drug is eluted over 30 days. 22 Although a reduction in in-stent restenosis has been well documented already with first-generation DESs, a high rate of late stent thrombosis initially gave rise to a lot of concern as to their use in ACS wherein thrombus formation is more common than in stable patients. 23, 24 Indeed, a recently published meta-analysis supported the notion of an incremental increase of stent thrombosis over time in patients receiving DESs. 25 However, the majority of randomized clinical trials do not address outcomes beyond 1 year. 9 In line with these observations, the rate of definite stent thrombosis in our study overall tended to be higher in patients receiving a DES compared with those receiving a BMS. However, the differences were not significant. Conceptually, the slightly higher rate of definite stent thrombosis after DES implantation at the 30-day follow-up could be because of technical issues, such as stent malapposition, residual A 30-day (a) and long-term major adverse cardiac and cerebrovascular events (MACCEs) (b) for patients with drug-eluting stents (DESs) and bare metal stents (BMSs), after propensity score ascertainment.
dissections, thrombus compression and/or displacement, thrombus burden and/or longer average stent length in the DES group (Table 2) . 24 However, the anticipated increased late stent thrombosis or very late stent thrombosis rate after DES implantation was not observed in our study, although the mean follow-up of 30-day survivors surpassed 2 years in the DES group. This observation is in line with the data of recently published trials, in which second-generation DESs reduced the rate of very late stent thrombosis when compared with first-generation DESs. 26 Of note, based on these results, second-generation DESs were preferentially used by our operations also in ACS patients with cardiogenic shock enrolled into the present registry.
Study limitations
The present study is based on an observational singlecenter registry. Thus, owing to its observational nature, selection bias, in spite of our attempts to account for them using propensity analysis, cannot be fully excluded. Indeed, patients with diabetes mellitus, hyperlipidemia, hypertension, NSTEMI and multivessel disease may be more likely to be treated with DESs, than those with complex lesions, unstable clinical conditions and perceived bad outcome. However, the risk profiles of the patients receiving DESs and BMSs were similar in this registry. Therefore, we could not identify any bias regarding the selected treatment strategy. In addition, potential bias was further accounted for using propensity score analysis.
Second, it is unclear whether the experience at our hospital would be consistent with that of other institutions where cardiogenic shock may be managed differently. Although we attempted to perform a propensity score adjustment, this approach does not account for unobservable differences (i.e. platelet activity, aspirin resistance among others). 27, 28 Moreover, owing to the observational character of the present study, we are not able to provide the accurate time duration of the cardiogenic shock before the PCI, which could additionally influence our results. Furthermore, the majority of DESs were implanted between 2010 and 2012 as compared with 2007 and 2009 (68 vs. 45%, P < 0.001). Therefore, the influence of intensive care medicine improvement on the better prognosis after DES implantation cannot be excluded. However, the mean follow-up was similar in both groups. Nevertheless, these additional treatment options remain important considerations in patients with cardiogenic shock. Therefore, future work, in particular prospective randomized trials, is needed in this important area.
Conclusion
Our observation is the first to indicate a survival benefit of DES use in patients with cardiogenic shock. However, owing to the importance of this observation for physicians taking care of patients with cardiogenic shock, this hypothesis should be further tested in a prospective, randomized clinical trial.
